{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"The second primary objective was to determine the percentage of participants with progression free survival following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies.\n\nWe define disease progression as disease recurrence within 180 days of transplant.","groups":[{"description":"Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).","id":"OG000","title":"Immunosuppression Taper"}],"paramType":"NUMBER","populationDescription":"54 patients were enrolled however 9 patients did not receive planned donor lymphocyte infusion. 45 patients were analyzed.","reportingStatus":"POSTED","timeFrame":"two years","title":"Percentage of Participants With Progression Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}